Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:1/27/2009

SOMERSET, N.J., Jan. 27 /PRNewswire-FirstCall/ -- Alfacell Corporation (OTC Bulletin Board: ACEL) today reported that it has conducted a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. At the pre-NDA meeting, the FDA provided guidance to the company recommending that an additional clinical trial be conducted in UMM patients that have failed one prior chemotherapy regimen, prior to submitting a NDA.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

The company's current financial situation does not allow it to pursue additional clinical trials until other sources of capital are secured. The company will effect a reduction in force on January 30, 2009 and otherwise reduce its operations to the minimum sustainable level required to pursue strategic alternatives and additional capital. Based upon these actions the company expects that its current cash reserves will enable it to maintain its reduced operations through December 2009. The company intends to continue to explore strategic alternatives and additional capital. Additionally, the company's board of directors has agreed to forgo cash compensation effective as of January 1, 2009.

About ONCONASE(R)

ONCONASE is a first-in-class therapeuti
'/>"/>

SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
2. Alfacell Receives Going Concern Audit Opinion
3. Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
4. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
5. Alfacell Hires Advisors to Advance Strategic Alternatives
6. Alfacell Receives NASDAQ Delisting Letter
7. Alfacell Receives NASDAQ Non-Compliance Notification
8. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
9. Alfacell Announces Retirement of Chief Executive Officer
10. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
11. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 The Kidney Cancer Association (KCA) has ... news magazine, Kidney Cancer News. , Bill Bro, KCA ... website maintained by an international news organization. When we began ... viewers.” , This month’s program highlights news of an enzyme ... in a recent study. Kidney Cancer News also presents a ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
(Date:7/30/2014)... 2014 While administrative claims and ... research for a relatively long period of time, ... the use of these ‘big data’ for comparisons ... combining today’s powerful computer technology with the plethora ... data’ holds significant promise for identifying optimal interventions ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 July ... (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication ... E. Hogan, Ph.D. Vice President of Life Sciences, a ... , Dr. Hogan will lead APDN’s drive ... business relationships with biotech and healthcare customers, provide guidance ...
Breaking Biology Technology:Grace Launches New REVELERIS® Prep Purification System 2Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... , , SAN MARINO, ... VRAL) has formed a wholly owned subsidiary called MetaCytoLytics, Inc. ... University of Colorado Professor M. Karen Newell called "metabolic disruption ... to generate energy from glucose or from fatty acids. ...
... , , EMERYVILLE, Calif., ... announced that it has agreed to sell an aggregate of four million ... $30.50 per share and $200 million aggregate principal amount of its 4.00% ... has granted the underwriters 30-day options to purchase up to an additional ...
... rate significantly reduced and Semen Sexing Technology achieves, ... For nine months ended June 30, 2009, Microbix Biosystems Inc. ... The third quarter had a small sales retraction that was ... forecast is for continued growth in sales. , "The 22% ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3Microbix Sales Grow 22% For Nine Months 2Microbix Sales Grow 22% For Nine Months 3Microbix Sales Grow 22% For Nine Months 4Microbix Sales Grow 22% For Nine Months 5
(Date:7/30/2014)... online today in the journal Scientific Reports , ... and Auroop Ganguly found that while global temperature is ... extremes. For instance, while each year,s average hottest and ... tend to fall within a wider range of potential ... observed. This means that even as overall temperatures rise, ...
(Date:7/29/2014)... methods and applications for imaging and manipulation of the ... were the inspiration behind Neurophotonics , a new ... optics and photonics. , The first issue coincides with ... States, and a special section features articles that lay ... impact that optics and photonics will have on advancing ...
(Date:7/29/2014)... sometimes need to get back to basics. UC ... study the impacts of the bumphead parrotfish ( ... two remote locations in the central Pacific Ocean. ... simulation, McCauley, an assistant professor in the Department ... colleagues sought to understand whether the world,s largest ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 2SPIE launches Neurophotonics journal with special section on BRAIN Initiative 3Underwater elephants 2Underwater elephants 3
... N.Y. To make paper, manufacturers must break down ... requires large amounts of energy and toxic chemicals like ... biodegradable proteins that accelerate chemical reactions using far less ... the job, in this case xylanases, don,t hold up ...
... the National Institute of Standards and Technology (NIST) and ... a simplified cell membrane to accurately detect and measure ... vaginosis (BV), at extraordinarily low concentrations. The work illustrates ... disease diagnosis. Caused by the bacteria Gardnerella ...
... release is available in German . ... of thousands of neurons in the brain. Nerve growth factors produced ... neurons; however, clinical tests with GDNF have not yielded in any ... Martinsried and their colleagues have now succeeded in demonstrating that GDNF ...
Cached Biology News:Expanding the range of nature's catalysts for industrial applications 2Expanding the range of nature's catalysts for industrial applications 3NIST cell membrane model studied as future diagnostic tool 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3
Functionally tested for consistent G-banding of chromosomes....
... BacVector Insect Cell Medium is optimized ... Ea4 Insect Cells. In this protein-free medium, ... 1 * 107 cells/ml with viabilities above ... plaque assays, where color from X-gluc staining ...
... Grace's Insect Medium is formuatled for ... including Sf9 and Sf21 cells. Grace's ... transfectioin because it does not contain ... interfere with transfection. Grace's Insect Medium, ...
TNM-FH Insect Medium 1 liter...
Biology Products: